Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease

BOSTON and LONDON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the "Company"), together with its subsidiary Palladio Biosciences, Inc. ("Palladio"), today announced it

Related Keywords

Boston ,Massachusetts ,United States ,London ,City Of ,United Kingdom ,Palladio Biosciences ,John Fraunces ,Saurabh Saha ,Palladio Biosciences Inc ,Centessa Pharmaceuticals ,Nasdaq ,Autosomal Dominant Polycystic Kidney Disease ,New Drug Application ,Chief Executive Officer ,Mayo Clinic ,Orphan Drug Designation ,Centessa ,Pharmaceuticals ,Doses ,First ,Subject ,Lobal ,Hase ,Action ,Study ,Ixivaptan ,Autosomal ,Dominant ,Polycystic ,Kidney ,Disease ,